Clinical Trial Update: Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment [NA]

View source ↗

Summary

A completed clinical trial comparing a PD-1 inhibitor plus lenvatinib versus a PD-1 inhibitor plus regorafenib in patients with unresectable hepatocellular carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• PD-1 inhibitor (unspecified)
• Regorafenib (regorafenib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellulcar Carcinoma | NA | Status: COMPLETED